glp-1 agonist and pancreatitis Risk of pancreatic cancer associated with receptor therapy Favorable Effects of GLP-1 Receptor
Description
Pausing GLP-1 Therapy Led to Consequences BMJ Medicine , followed more than 333,000 American veterans with type 2 diabetes for three years
2016 February;26(2):85-89 This patient-centered case vignette offers insight into how best to choose among additional oral agents, basal insulin, or the newer GLP-1 receptor agonists
Chequin, A
These events were dose-dependent, primarily of mild to moderate severity, and were partially alleviated by lower initial doses (2 mg vs
R., Bower, R
